← Eichor
Study identifier: NCT07561814 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data

Condition: Pancreatic Cancer  ·  Sponsor: Shanghai Zhongshan Hospital

PhaseN/A
Planned participants1030
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress. The main questions it aims to answer are: * Can combining these types of data more accurately estimate how long a person might survive? * Can it better predict the risk of recurrence? Participants will not have any extra tests or treatments. They will: * Allow researchers to collect information from their existing medical records (such as surgery reports, imaging, and lab results) * Receive a follow-up phone call for up to 3 years to share health updates(about every 3 months for the prospective cohort).

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (1)

Zhongshan Hospital Affiliated to Fudan UniversityShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07561814